

Imbalance of peptidoglycan biosynthesis alters the cell surface charge of *Listeria monocytogenes*

Lisa Maria Schulz^a, Patricia Rothe^c, Sven Halbedel^{c,d}, Angelika Gründling^b,
Jeanine Rismondo^{a,b,*}

^a Department of General Microbiology, Institute of Microbiology and Genetics, GZMB, Georg-August University Göttingen, Grisebachstr. 8, 37077 Göttingen, Germany

^b Section of Molecular Microbiology and Medical Research Council Centre for Molecular Bacteriology and Infection, Imperial College London, London SW7 2AZ, United Kingdom

^c FG11, Division of Enteropathogenic Bacteria and Legionella, Robert Koch Institute, Burgstraße 37, 38855 Wernigerode, Germany

^d Institute for Medical Microbiology and Hospital Hygiene, Otto von Guericke University Magdeburg, Leipziger Straße 44, 39120 Magdeburg, Germany

ARTICLE INFO

Keywords:

Listeria monocytogenes
Peptidoglycan biosynthesis
Lysozyme
Wall teichoic acid

ABSTRACT

The bacterial cell wall is composed of a thick layer of peptidoglycan and cell wall polymers, which are either embedded in the membrane or linked to the peptidoglycan backbone and referred to as lipoteichoic acid (LTA) and wall teichoic acid (WTA), respectively. Modifications of the peptidoglycan or WTA backbone can alter the susceptibility of the bacterial cell towards cationic antimicrobials and lysozyme. The human pathogen *Listeria monocytogenes* is intrinsically resistant towards lysozyme, mainly due to deacetylation and *O*-acetylation of the peptidoglycan backbone via Pgda and OatA. Recent studies identified additional factors, which contribute to the lysozyme resistance of this pathogen. One of these is the predicted ABC transporter, EslABC. An *eslB* mutant is hyper-sensitive towards lysozyme, likely due to the production of thinner and less *O*-acetylated peptidoglycan. Using a suppressor screen, we show here that suppression of *eslB* phenotypes could be achieved by enhancing peptidoglycan biosynthesis, reducing peptidoglycan hydrolysis or alterations in WTA biosynthesis and modification. The lack of EslB also leads to a higher negative surface charge, which likely stimulates the activity of peptidoglycan hydrolases and lysozyme. Based on our results, we hypothesize that the portion of cell surface exposed WTA is increased in the *eslB* mutant due to the thinner peptidoglycan layer and that latter one could be caused by an impairment in UDP-*N*-acetylglucosamine (UDP-GlcNAc) production or distribution.

Introduction

In recent years, antibiotic resistance became a serious threat for public health. One of the main targets of currently available antibiotics is the bacterial cell wall (Fig. 1). In Gram-positive bacteria, the cell wall consists of a thick layer of peptidoglycan and cell wall polymers, which are either tethered to the cell membrane or covalently linked to peptidoglycan and referred to as lipoteichoic (LTA) and wall teichoic acid (WTA), respectively. Peptidoglycan biosynthesis starts in the cytoplasm by the conversion of UDP-*N*-acetylglucosamine (UDP-GlcNAc) to UDP-*N*-acetylmuramic acid (UDP-MurNAc) via MurA and MurB. The activity of the UDP-GlcNAc 1-carboxyvinyltransferase MurA can be specifically inhibited by the antibiotic fosfomycin (Fig. 1) (Kahan et al., 1974). In the subsequent steps, which are depicted in Fig. 1, the peptidoglycan

precursor lipid II is synthesized in the cytoplasm and transported across the membrane by the flippase MurJ (Meeske et al., 2015; Ruiz, 2008; Sham et al., 2014). Lipid II is then incorporated into the growing glycan strand by members of the SEDS (shape, elongation, division, sporulation) protein family, namely RodA and FtsW, which act in concert with class B penicillin binding proteins (PBPs) that have a transpeptidase activity (Cho et al., 2016; Leclercq et al., 2017; Taguchi et al., 2019). Recent findings led to the conclusion that class A PBPs, which possess a glycosyltransferase and a transpeptidase domain, are mainly involved in filling gaps and/or repair defects in the peptidoglycan mesh, rather than being the main enzymes involved in peptidoglycan polymerization and crosslinking (Cho et al., 2016; Dion et al., 2019; Vigouroux et al., 2020). The ability of bacterial cells to elongate and divide depends on the activity of peptidoglycan hydrolases. In the Gram-positive model organism

* Corresponding author at: Department of General Microbiology, Institute of Microbiology and Genetics, GZMB, Georg-August University Göttingen, Grisebachstr. 8, 37077 Göttingen, Germany.

E-mail address: jrismon@gwdg.de (J. Rismondo).

<https://doi.org/10.1016/j.tcs.2022.100085>

Received 5 October 2022; Received in revised form 19 October 2022; Accepted 19 October 2022

Available online 20 October 2022

2468-2330/© 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).




Fig. 1. Schematic of the UDP-GlcNAc, peptidoglycan and wall teichoic acid biosynthesis pathway. UDP-GlcNAc, which is required for peptidoglycan and wall teichoic acid (WTA) biosynthesis, is synthesized from Fructose-6-phosphate in a four-step reaction catalyzed by GlmS, GlmM, GlmU and GlmR. MurA, an UDP-GlcNAc-1-carboxyvinyltransferase catalyzing the first step of peptidoglycan biosynthesis, and MurB convert UDP-GlcNAc to UDP-MurNAc. Lipid II is produced in subsequent steps, which are performed by MurCDEF, Alr, Ddl, MraY and MurG, flipped across the membrane by MurJ and inserted into the growing glycan strand by glycosyltransferases (GTases). Finally, peptidoglycan is crosslinked by the action of transpeptidases (TPases) (Pazos and Peters, 2019). UDP-GlcNAc also serves as a substrate of TarO, the first enzyme of the WTA biosynthesis pathway. After the WTA polymer is synthesized by a subset of enzymes, it is transported across the membrane via TarGH (Brown et al., 2013) and, in case of *L. monocytogenes* 10403S, decorated with GlcNAc residues (Shen et al., 2017). UDP-GlcNAc-consuming enzymes are labelled in red. Antibiotics targeting different steps of the UDP-GlcNAc, peptidoglycan and WTA biosynthesis pathways or degrade peptidoglycan are depicted in bold (Campbell et al., 2011; Pensinger et al., 2021; Sarkar et al., 2017). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

Bacillus subtilis, which is closely related to *L. monocytogenes*, two DL-endopeptidases, CwlO and LytE, are essential for cell elongation. In addition to its role in cell elongation, LytE is also involved in cell separation (Carballido-López et al., 2006; Ohnishi et al., 1999; Vollmer et al., 2008). Both enzymes cleave the peptide bond between D-glutamic acid and meso-diamino pimelic acid of the peptidoglycan peptide, thereby allowing the insertion of new peptidoglycan material (Yamaguchi et al., 2004). Lack of CwlO results in cell shortening, while absence of CwlO and LytE is lethal (Domínguez-Cuevas et al., 2013; Hashimoto et al., 2012). Peptidoglycan biosynthesis and hydrolysis need to be tightly regulated to prevent cell lysis. In *B. subtilis*, this regulation is partly achieved by controlling expression of *cwlO* and *lytE* via the essential two-component system WalRK, whose expression is for instance induced during heat stress (Bisicchia et al., 2007; Dubrac et al., 2008; Takada et al., 2018). On the other hand, activity of CwlO depends on a direct protein-protein interaction with the ABC transporter FtsEX (Meisner et al., 2013). The FtsEX-dependent regulation of *B. subtilis* CwlO further depends on the presence of two cofactors, SweC and SweD (Brunet et al., 2019; Rismondo and Schulz, 2021).

UDP-GlcNAc is synthesized from fructose-6-phosphate via a four-step reaction catalyzed by GlmS, GlmM, GlmU and GlmR and serves as a substrate of MurA. Recent findings suggest that the UDP-GlcNAc biosynthetic pathway can be inhibited by *trans*-cinnamaldehyde (*t*-Cin) (Fig. 1) (Pensinger et al., 2021; Sun et al., 2021). UDP-GlcNAc is also consumed by TarO/TagO, which catalyzes the first committed step for the synthesis of WTA (Soldo et al., 2002). The activity of TarO/TagO can be blocked by tunicamycin, which also affects the activity of MraY at high concentrations (Campbell et al., 2011; Hakulinen et al., 2017; Price and Tsvetanova, 2007; Watkinson et al., 1971). In *L. monocytogenes* 10403S, WTA is composed of a glucose-glucose(Glc-Glc)-glycerol phosphate-GlcNAc-*N*-acetylmannosamine (ManNAc) linker unit and an

anionic ribitol phosphate backbone, which can be modified with rhamnose, GlcNAc and D-alanine residues (Shen et al., 2017). The modification of WTA with positively charged D-alanine residues helps to mask the negative charge of the ribitol phosphate backbone, thereby conferring resistance towards cationic antimicrobial peptides and lysozyme (Brown et al., 2013; Vadyvaloo et al., 2004).

Lysozyme is an enzyme that cleaves the β -1,4-glycosidic bond between MurNAc and GlcNAc of the bacterial peptidoglycan backbone and is found in human body fluids such as tears, saliva and mucus. *L. monocytogenes* is intrinsically resistant towards lysozyme, which is mainly achieved by modifications of the peptidoglycan. PgdA, an *N*-deacetylase, and OatA, an *O*-acetyltransferase, deacetylate and acetylate the GlcNAc and MurNAc residues, respectively (Aubry et al., 2011; Boneca et al., 2007). In addition to peptidoglycan modifying enzymes, lysozyme resistance of *L. monocytogenes* is affected by the activity of the predicted carboxypeptidase PbpX, the non-coding RNA Rli31 and the transcription factor DegU (Burke et al., 2014). Interestingly, it was also observed that the lack of components of the putative ABC transporter EslABC leads to a strong reduction in lysozyme resistance (Burke et al., 2014; Durack et al., 2015; Rismondo et al., 2021b). Recently, we could show that the absence of EslB, one of the transmembrane proteins of the EslABC transporter, resulted in the production of a thinner peptidoglycan layer and a reduction in *O*-acetylation of the peptidoglycan, which likely contributes to the reduced lysozyme resistance. Additionally, we observed that the *eslB* mutant is unable to grow in media containing high sugar concentrations and that the strain has a cell division defect (Rismondo et al., 2021b; Rismondo and Schulz, 2021).

In the current study, we used a suppressor screen to gain further insights into the role of EslABC on the physiology of *L. monocytogenes*. This screen revealed that phenotypes of the *eslB* mutant can either be suppressed by enhancing peptidoglycan biosynthesis, reducing

peptidoglycan hydrolysis or by altering WTA production or modification. Using a cytochrome C assay, we further demonstrate that the lack of *EslB* manifests in a higher negative surface charge, which likely affects the activity of peptidoglycan hydrolases and provides an additional explanation for the increased lysozyme sensitivity of the *eslB* mutant.

Materials and methods

Bacterial strains and growth conditions

All strains and plasmids used in this study are listed in Table S1. *Escherichia coli* strains were grown in Luria-Bertani (LB) medium and *Listeria monocytogenes* strains in brain heart infusion (BHI) medium at 37 °C unless otherwise stated. Where required, antibiotics and supplements were added to the medium at the following concentrations: for *E. coli* cultures, ampicillin (Amp) at 100 µg ml⁻¹, kanamycin (Kan) at 30 µg ml⁻¹, and for *L. monocytogenes* cultures, chloramphenicol (Cam) at 10 µg ml⁻¹, erythromycin (Erm) at 5 µg ml⁻¹, Kan at 30 µg ml⁻¹, nalidixic acid (Nal) at 30 µg ml⁻¹, streptomycin (Strep) at 200 µg ml⁻¹ and IPTG at 1 mM.

Strain and plasmid construction

All primers used in this study are listed in Table S2. For the construction of pIMK3-*murA*, pIMK3-*glmR*, pIMK3-*glmU* and pIMK3-*glmM*, the *murA*, *glmR*, *glmU* and *glmM* genes were amplified using primer pairs JR90/JR91, JR134/JR135, JR136/JR137 and JR138/JR139, respectively, cut with *NcoI* and *SalI* and ligated into plasmid pIMK3 that had been cut with the same enzymes. The resulting plasmids pIMK3-*murA*, pIMK3-*glmR*, pIMK3-*glmU* and pIMK3-*glmM* were recovered in *E. coli* XL1-Blue yielding strains XL1 Blue pIMK3-*murA* (EJR52), XL1 Blue pIMK3-*glmR* (EJR106), XL1 Blue pIMK3-*glmU* (EJR107) and XL1 Blue pIMK3-*glmM* (EJR108). Next, plasmids pIMK3-*murA*, pIMK3-*glmR*, pIMK3-*glmU* and pIMK3-*glmM* were transformed into *E. coli* S17-1 yielding strains S17-1 pIMK3-*murA* (EJR59), S17-1 pIMK3-*glmR* (EJR132), S17-1 pIMK3-*glmU* (EJR133) and S17-1 pIMK3-*glmM* (EJR134). *E. coli* strain S17-1 pIMK3-*murA* (EJR59) was used as a donor strain to transfer plasmid pIMK3-*murA* by conjugation into *L. monocytogenes* strains 10403S (ANG1263) and 10403SΔ*eslB*₍₂₎ (ANG5662) using a previously described method (Lauer et al., 2002). This resulted in the construction of strains 10403S pIMK3-*murA* (LJR26) and 10403SΔ*eslB*₍₂₎ pIMK3-*murA* (LJR27), in which the expression of *murA* is under the control of an IPTG-inducible promoter. Strains carrying the empty pIMK3 vector were used as controls. For this purpose, pIMK3 was transformed into *E. coli* S17-1 yielding strain EJR58. S17-1 pIMK3 was subsequently used as a donor strain to transfer plasmid pIMK3 by conjugation into *L. monocytogenes* strains 10403S (ANG1263) and 10403SΔ*eslB*₍₂₎ (ANG5662), which resulted in the construction of strains 10403S pIMK3 (LJR24) and 10403SΔ*eslB*₍₂₎ pIMK3 (LJR25). For the construction of pIMK3-*glsM*, the *glsM* gene was amplified using primer pair JR140/JR141. The resulting PCR product was cut with *BamHI* and *XmaI* and ligated into plasmid pIMK3 that had been cut with the same enzymes. Plasmid pIMK3-*glsM* was recovered in *E. coli* XL1-Blue and subsequently transformed into *E. coli* S17-1 yielding strains XL1 Blue pIMK3-*glsM* (EJR112) and S17-1 pIMK3-*glsM* (EJR135), respectively. *E. coli* strains S17-1 pIMK3-*glmR* (EJR132), S17-1 pIMK3-*glmU* (EJR133), S17-1 pIMK3-*glmM* (EJR134) and S17-1 pIMK3-*glsM* (EJR135) were used to transfer plasmids pIMK3-*glmR*, pIMK3-*glmU*, pIMK3-*glmM* and pIMK3-*glsM* by conjugation into *L. monocytogenes* strain 10403SΔ*eslB*₍₂₎ (ANG5662) yielding strains 10403SΔ*eslB*₍₂₎ pIMK3-*glmR* (LJR63), 10403SΔ*eslB*₍₂₎ pIMK3-*glmU* (LJR64), 10403SΔ*eslB*₍₂₎ pIMK3-*glmM* (LJR65) and 10403SΔ*eslB*₍₂₎ pIMK3-*glsM* (LJR66).

For the construction of a markerless deletion of *cwlo* (*lmg_01743*), 1-kb DNA fragments up- and downstream of *cwlo* were amplified by PCR with primers LMS106/107 and LMS104/105. The resulting PCR

products were fused in a second PCR using primers LMS105/106, the product cut with *BamHI* and *KpnI* and ligated into pKSV7 that had been cut with the same enzymes. The resulting plasmid pKSV7-Δ*cwlo* was recovered in *E. coli* XL1-Blue yielding strain XL1 Blue pKSV7-Δ*cwlo* (EJR63). Plasmid pKSV7-Δ*cwlo* was subsequently transformed into *L. monocytogenes* 10403S and *cwlo* deleted by allelic exchange according to a previously published method (Camilli et al., 1993) yielding strain 10403SΔ*cwlo* (LJR37). Since attempts of producing electrocompetent *cwlo* cells were unsuccessful, plasmid pIMK3-*cwlo* was first conjugated into strain 10403SΔ*cwlo* (LJR37), which allows for IPTG-inducible expression of *cwlo*, and resulting in the construction of strain 10403SΔ*cwlo* pIMK3-*cwlo* (LJR103). For the construction of pIMK3-*cwlo*, *cwlo* was amplified using the primer pair LMS226 and LMS227. The fragment was cut with *NcoI* and *BamHI*, ligated into pIMK3 that had been cut with the same enzymes and recovered in *E. coli* XL1-blue and S17-1, yielding strains EJR114 and EJR115, respectively. To generate a *cwlo eslB* double mutant, plasmid pKSV7-Δ*eslB* was first transformed into *L. monocytogenes* strain 10403SΔ*cwlo* pIMK3-*cwlo* (LJR103) resulting in strain 10403SΔ*cwlo* pIMK3-*cwlo* pKSV7-Δ*eslB* (LJR114). The *eslB* gene was then deleted by allelic exchange. This resulted in the construction of strain 10403SΔ*cwlo* Δ*eslB* pIMK3-*cwlo* (LJR119).

For the construction of promoter-*lacZ* fusions, the plasmid pAC7 was used. The promoter region of the *dlt* operon was amplified from genomic DNA of the *L. monocytogenes* wildtype 10403S and the *eslB* suppressor strain 10403S Δ*eslB*₍₃₎ P_{dlt}* (ANG5746) containing a mutation 31 bp upstream of the ATG start codon, using the primer pair LMS93 and LMS94. The PCR products were digested with *BamHI* and *EcoRI* and ligated into pAC7. The resulting plasmids pAC7-P_{dlt} and pAC7-P_{dlt}* were recovered in XL1 Blue resulting in strains XL1 Blue pAC7-P_{dlt} (EJR50) and XL1 Blue pAC7-P_{dlt}* (EJR51). Subsequently, both plasmids were integrated into the *amyE* site of the *B. subtilis* wildtype strain 168, resulting in *B. subtilis* strains 168 pAC7-P_{dlt} (BLMS4) and 168 pAC7-P_{dlt}* (BLMS5), respectively.

Generation of *eslB* suppressors and whole genome sequencing

For the generation of *eslB* suppressors, overnight cultures of three independently generated *L. monocytogenes* *eslB* mutants, strains 10403SΔ*eslB*₍₁₎ (ANG4275), 10403SΔ*eslB*₍₂₎ (ANG5662) and 10403SΔ*eslB*₍₃₎ (ANG5685), were adjusted to an OD₆₀₀ of 1. 100 µl of 10⁻¹ and 10⁻² dilutions of these cultures were plated on BHI plates containing (A) 0.5 M sucrose and 0.025 µg ml⁻¹ penicillin, (B) 0.5 M sucrose and 0.05 µg ml⁻¹ penicillin or (C) 100 µg ml⁻¹ lysozyme, conditions under which the *eslB* mutant is unable to grow while the *L. monocytogenes* wildtype strain 10403S can grow. The plates were incubated at 37 °C overnight and single colonies were re-streaked on BHI plates. This procedure was repeated at least three independent times per condition. The genome sequence of a selection of *eslB* suppressors was determined by whole genome sequencing (WGS) using an Illumina MiSeq machine and a 150 paired end Illumina kit as described previously (Rismondo et al., 2021b). The reads were trimmed, mapped to the *L. monocytogenes* 10403S reference genome (NC_017544) and single nucleotide polymorphisms (SNPs) with a frequency of at least 90 % identified using CLC workbench genomics (Qiagen) and Geneious Prime® v.2021.0.1. The whole genome sequencing data were deposited at the European Nucleotide Archive (ENA) under accession number PRJEB55822.

Determination of resistance towards antimicrobials

For the disk diffusion assays, overnight cultures of the indicated *L. monocytogenes* strains were adjusted to an OD₆₀₀ of 0.1. 100 µl of cultures were spread on BHI agar plates using a cotton swap. Plates contained 1 mM IPTG were indicated. 6 mm filter disks were placed on top of the agar surface, soaked with 20 µl of the appropriate antibiotic stock solution and the plates were incubated at 37 °C. The diameter of




Fig. 2. Mutation P159L in *prpC* suppresses *eslB* phenotypes. (A) Drop dilution assay. Dilutions of *L. monocytogenes* strains 10403S (wt), $\Delta eslB_{(2)}$, $\Delta eslB_{(2)}$ compl., and $\Delta eslB_{(2)}$ *prpC*^{P159L} were spotted on BHI plates, BHI plates containing 100 μ g/ml lysozyme or containing 0.5 M sucrose and 0.025 μ g/ml penicillin G and were incubated at 37 °C or on BHI plates and were incubated at 42 °C. (B) Western blot. Protein samples of strains 10403S, $\Delta eslB_{(2)}$, $\Delta eslB_{(2)}$ compl. and $\Delta eslB_{(2)}$ *prpC*^{P159L} were separated by SDS PAGE and transferred to a PVDF membrane. MurA was detected using a MurAA-specific antibody as described in the methods section. Protein samples of *L. monocytogenes* wildtype strain EGD-e and a *clpC* mutant were used as controls. A western blot showing DivIVA levels serves as a loading control. MurA level in the protein samples were quantified and plotted. For statistical analysis, an unpaired two-tailed *t*-test was used (* *p* ≤ 0.05).

the inhibition zone was measured the next day. The following stock solutions were used: 50 mg ml⁻¹ fosfomicin, 1 mg ml⁻¹ *t*-Cin, 5 mg ml⁻¹ tunicamycin, 15 mg ml⁻¹ D-cycloserine, 60 mg ml⁻¹ nisin, 30 mg ml⁻¹ vancomycin, 5 mg ml⁻¹ moenomycin, 1 mg ml⁻¹ penicillin, 10 mg ml⁻¹ ampicillin and 250 mg ml⁻¹ bacitracin.

Spot plating assays

Overnight cultures of *L. monocytogenes* strains were adjusted to an OD₆₀₀ of 1 and serially diluted to 10⁻⁶. 5 μ l of each dilution were spotted on BHI agar plates, BHI agar plates containing 0.5 M sucrose and 0.025 μ g ml⁻¹ penicillin; 100 μ g ml⁻¹ lysozyme; 0.025 μ g/ml moenomycin, 500 μ l DMSO (\geq 99.5 %), 0.05 μ g ml⁻¹ or 0.5 μ g ml⁻¹ tunicamycin and

plates incubated at 37 °C unless otherwise stated. Where indicated, plates were supplemented with 1 mM IPTG or 20 mM MgCl₂. Images of plates were taken after 20–24 h of incubation.

Cell length analysis

Overnight cultures of the indicated *L. monocytogenes* strains were inoculated to an OD₆₀₀ of 0.1 and grown to an OD₆₀₀ of 0.3–0.6 at 37 °C with agitation in BHI medium or BHI medium containing 1 mM IPTG and the appropriate antibiotic. To stain the bacterial membranes, 800 μ l of the bacterial cultures were mixed with 40 μ l of 100 μ g ml⁻¹ Nile red and incubated for 20 min at 37 °C. The cells were washed twice in PBS buffer and subsequently re-suspended in the same buffer. Cells were

then fixed in 1.12 % paraformaldehyde for 20 min at room temperature in the dark and 1–1.5 μ l of the cell suspension was spotted on microscope slides covered with a thin agarose layer (1.5 % in ddH₂O). Phase contrast and fluorescence images were taken using a Zeiss Axioskop 40 microscope equipped with an EC Plan-NEOFLUAR 100X/1.3 objective (Carl Zeiss, Göttingen, Germany) and coupled to an AxioCam MRm camera. Filter set 43 was used for the detection of the Nile red signal. The images were processed using the Axio Vision software (release 4.7). The length of 50 cells per replicate was measured for each strain and the mean calculated. Statistical analysis was performed using the software GraphPad Prism (version 8).

Isolation of cellular proteins and western blotting

Bacteria from a 20 ml culture were harvested by centrifugation and washed with ZAP buffer (10 mM Tris-HCl, pH 7.5, 200 mM NaCl). The cells were subsequently resuspended in 1 ml ZAP buffer containing 1 mM PMSF and disrupted by sonication. Cellular debris was removed by centrifugation, the resulting supernatant collected and separated by SDS polyacrylamide gel electrophoresis (PAGE). Proteins were transferred onto positively charged polyvinylidene fluoride (PVDF) membranes using a semi-dry transfer unit. MurA and DivIVA were detected using a polyclonal rabbit antiserum raised against the *B. subtilis* MurAA protein (Kock et al., 2004), which also cross reacts with the *L. monocytogenes* MurA protein, and DivIVA (Marston et al., 1998) as primary antibody and an anti-rabbit immunoglobulin G conjugated to horseradish peroxidase antibody as the secondary antibody. Blots were developed using ECL chemiluminescence reagents (Thermo Scientific) and imaged using a chemiluminescence imager (Vilber Lourmat).

Cytochrome C binding assay

Cytochrome C binding assays were performed as previously described (Kang et al., 2015). Briefly, overnight cultures of *L. monocytogenes* were used to inoculate fresh cultures to an OD₆₀₀ of 0.05 in 4 ml BHI medium and the cultures were grown to an OD₆₀₀ of 0.6–0.8 at 37 °C and 200 rpm. Bacteria from 2 ml of the culture were harvested by centrifugation at 16,200 \times g for 1 min. Cells were then washed twice with 20 mM MOPS (3-(N-morpholino) propanesulfonic acid) buffer (pH 7) and adjusted to an OD₆₀₀ of 0.25 in the same buffer. Cytochrome C was added at a final concentration of 50 μ g ml⁻¹ and the suspension was incubated in the dark for 10 min at room temperature. The suspension was centrifuged for 5 min at 16,200 \times g, the supernatant removed and the absorbance of the supernatant was measured at 410 nm (OD₄₁₀ + cells). A reaction without cells was used as blank (OD₄₁₀ – cells). The percentage of bound cytochrome C was calculated as follows:

$$\% \text{ cytochrome C bound} = 100 - [(OD_{410} + \text{cells}) / (OD_{410} - \text{cells})]$$

β -galactosidase assay

To compare the *dlt* promoter activity of the *L. monocytogenes* wildtype and suppressor strain 10403S Δ *eslB*₍₃₎ *P*_{*dlt*}* (ANG5746), β -galactosidase assays were performed. For this purpose, promoter-*lacZ* fusions were integrated into the *amyE* locus of *B. subtilis* 168. The resulting *B. subtilis* strains were grown in CSE-glucose minimal medium at 37 °C to an OD₆₀₀ of 0.5–0.8, bacteria from a culture aliquot harvested and the β -galactosidase activity determined as described previously (Miller, 1972).

Results

ΔeslB phenotypes are restored in the presence of excess Mg²⁺

The *eslABC* operon encodes the putative ABC transporter EslABC and the RpiR transcriptional regulator EslR. Absence of the




Fig. 3. Alterations in the resistance of the *eslB* mutant towards cell wall-targeting antibiotics. Disk diffusion assay. *L. monocytogenes* strains 10403S (wt), Δ *eslB*₍₂₎ and Δ *eslB*₍₂₎ compl. were spotted on BHI plates. Antibiotic-soaked disks placed on top the agar surface and the plates incubated for 24 h at 37 °C. The inhibition zones for the indicated strains were measured and the average values and standard deviation of at least three independent experiments were plotted. For statistical analysis, a one-way ANOVA coupled with a Dunnett's multiple comparison test was used (** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$).

transmembrane component EslB leads to a multitude of phenotypes including a cell division defect, decreased lysozyme resistance, the production of a thinner cell wall and a growth defect in media containing high sugar concentrations (Rismondo et al., 2021b). In addition, we observed that the growth of the *eslB* mutant is severely affected when grown on BHI plates at 42 °C (Fig. 2A). So far, the cellular function of the transporter EslABC and how it is mechanistically linked to cell division and cell wall biosynthesis in *L. monocytogenes* is unknown. Generally, many cell wall defects can be rescued by the addition of Mg²⁺, however, the reason for this is still debated. Recently, it was speculated that binding of Mg²⁺ to the cell wall inhibits peptidoglycan hydrolases and thereby stabilizes the bacterial cell wall (Tesson et al., 2022). As the phenotypic defects of the *eslB* mutant suggest that peptidoglycan biosynthesis might be impaired, we speculated that the addition of Mg²⁺ should rescue the growth of this strain. To test this hypothesis, the *L. monocytogenes* wildtype 10403S, the Δ *eslB* mutant and the Δ *eslB* complementation strain were inoculated on BHI plates containing sucrose and penicillin, lysozyme or were incubated at 42 °C in the absence or presence of 20 mM MgCl₂. The addition of Mg²⁺ could restore the growth of the Δ *eslB* mutant under all conditions tested (Fig. S1), further supporting the hypothesis that peptidoglycan biosynthesis is impaired in *L. monocytogenes* cells lacking EslB.

Resistance profile of the *eslB* mutant towards cell wall-targeting antibiotics

To narrow down which point of the peptidoglycan biosynthesis pathway is impaired in the *eslB* mutant, we performed disk diffusion assays with antibiotics that target different steps of this pathway (Fig. 1). Compared to the wildtype, the *eslB* mutant was more sensitive towards *t*-Cin and fosfomycin (Fig. 3), which target the UDP-GlcNAc biosynthetic pathway and MurA, respectively (Marquardt et al., 1994; Pensinger et al., 2021; Sun et al., 2021). In contrast, the resistance towards D-cycloserine, nisin, vancomycin, moenomycin, penicillin and bacitracin (Fig. 1), which target processes downstream of MurA, was not altered in the *eslB* mutant (Fig. S2). The *eslB* mutant was more resistant towards tunicamycin, whose main target at low concentrations is TarO,

Table 1
Identified sequence alterations in *L. monocytogenes* *eslB* deletion strains and suppressors.

Strain number	Reference position ¹	Type ²	Ref ³	Allele ⁴	Frequency ⁵	Annotations ⁶	AA change ⁷	Condition ⁸
ANG4275 10403SΔ <i>eslB</i> ₍₁₎	2425786–2425875	DEL			100 %	<i>lmo2396</i> , internalin	30 aa deletion	
ANG5386	2583855	DEL	T	–	100 %	<i>murZ</i> , UDP- <i>N</i> -acetylglucosamine 1-carboxyvinyltransferase	M240fs	P
ANG5479	310043	SNV	G	A	100 %	<i>walK</i> , histidine kinase of TCS WalRK	R553H	P
ANG5480	309234	SNV	C	G	100 %	<i>walK</i> , histidine kinase of TCS WalRK	N283E	P
ANG5488	2537835	SNV	C	G	100 %	<i>ftsX</i> , membrane component of ABC transporter FtsEX	G243R	P
ANG5489	310094	SNV	C	T	100 %	<i>walK</i> , histidine kinase of TCS WalRK	A570V	P
ANG5499	1491251	DEL	T	–	100 %	<i>reoM</i> , regulator of MurA degradation	L23fs	P
ANG5662 10403SΔ <i>eslB</i> ₍₂₎	–							
ANG5698	2582654	DEL	G	–	100 %	<i>murZ</i> , UDP- <i>N</i> -acetylglucosamine 1-carboxyvinyltransferase	Q307fs	P
ANG5699	310,133	SNV	T	C	97.4 %	<i>walK</i> , histidine kinase of TCS WalRK	I583T	P
ANG5708	1852252	SNV	G	A	100 %	<i>prpC</i> , serine threonine phosphatase	P159L	P
ANG5710	2537273	SNV	C	T	98 %	<i>cwlO</i> , peptidoglycan DL-endopeptidase	R106H	P
ANG5714	2538568	SNV	G	A	98.4 %	<i>ftsE</i> , ATP binding protein of ABC transporter FtsEX	Q220-	P
ANG5733	308133	SNV	A	G	100 %	<i>walR</i> , response regulator of TCS WalRK	S216G	L
ANG5734	309772	SNV	C	G	100 %	<i>walK</i> , histidine kinase of TCS WalRK	H463D	L
ANG5737	309085	SNV	G	T	100 %	<i>walK</i> , histidine kinase of TCS WalRK	V234L	L
ANG5741	309824	SNV	G	A	100 %	<i>walK</i> , histidine kinase of TCS WalRK	R480H	L
ANG5685 10403SΔ <i>eslB</i> ₍₃₎	–							
ANG5717	1921373	SNV	G	A	100 %	<i>pbpA1</i> , bifunctional penicillin binding protein	G125D	P
ANG5729	1090622	SNV	C	T	100 %	<i>tarL</i> , teichoic acid ribitol-phosphate polymerase	P282L	P
ANG5746	988580	SNV	T	C	100 %	Promoter of <i>dlt</i> operon, involved in D-alanylation of wall teichoic and lipoteichoic acids	–	L

¹ Reference position is based on the position in the *L. monocytogenes* 10403S reference genome (NC_01744).

² Type of mutation: SNV = single nucleotide variant; DEL = nucleotide deletion.

³ Ref indicates base in reference genome.

⁴ Allele indicates base at the same position in the sequenced strain.

⁵ Frequency at which the base change was found in the sequenced strain.

⁶ TCS = Two-component system.

⁷ AA change indicates the resulting amino acid change in the protein found in the reference strains as compared to the sequenced strain.

⁸ Condition, which was used to raise suppressors. L = BHI plates containing 100 µg/ml lysozyme. P = BHI plates containing 0.5 M sucrose and 0.025 or 0.05 µg/ml penicillin.

the first enzyme functioning in the WTA biosynthesis pathway (Fig. 3). As we have seen above, the inhibition of WTA biosynthesis seems to be beneficial for the *eslB* mutant likely due to an increased flux of UDP-GlcNAc towards peptidoglycan biosynthesis. This antibiotic screen therefore suggests that one of the limiting factors of the *eslB* mutant might be the synthesis or correct distribution of UDP-GlcNAc, a precursor, which is used for both peptidoglycan biosynthesis and the synthesis and modification of WTA. This hypothesis is supported by the observation that overproduction of GlmM and GlmR, two proteins involved in the production of UDP-GlcNAc, can partially suppress the *eslB* phenotypes (Fig. S3).

Isolation of *eslB* suppressor mutants


To gain insights into the function of EslABC, we took advantage of the observation that the *eslB* mutant forms suppressors when grown on BHI plates that contain either 100 µg ml⁻¹ lysozyme, or 0.5 M sucrose and 0.025 or 0.05 µg ml⁻¹ penicillin. Genomic alterations present in independently isolated *eslB* suppressors were determined by whole genome sequencing. A large subset of *eslB* suppressors had mutations in *walR* (*lmo0287*) or *walK* (*lmo0288*), which encode the WalRK two-component system that is involved in cell wall metabolism (Dubrac et al., 2008; Howell et al., 2003). In addition, we identified mutations that mapped to genes associated with peptidoglycan biosynthesis (*murZ* (*lmo2552*), *reoM* (*lmo1503*), *prpC* (*lmo1821*), *pbpA1* (*lmo1892*)), peptidoglycan hydrolysis (*cwlO* (*lmo2505*), *spl*), *ftsX* (*lmo2506*), *ftsE* (*lmo2507*)) and wall teichoic acid (WTA) biosynthesis and modification

(*tarL* (*lmo1077*), *dltX* (promoter region, *lmg02074*)) (Table 1).

Suppression of *eslB* phenotypes by increased MurA levels

Under sucrose penicillin stress, two *eslB* suppressors with mutations in *murZ* and one *eslB* suppressor with a mutation in *reoM* or *prpC* were isolated. The proteins encoded by all three of these genes affect MurA protein levels (Wamp et al., 2022, 2020). Drop dilution assays were performed to assess whether mutations in *murZ*, *reoM* and *prpC* suppress the growth defect of the *eslB* mutant in the presence of sucrose and penicillin as well as other conditions under which the growth of the *eslB* mutant is severely affected. As expected, the growth of the *L. monocytogenes* strains 10403SΔ*eslB*₍₁₎ *murZ*^{M240fs}, 10403SΔ*eslB*₍₂₎ *murZ*^{Q307fs}, 10403SΔ*eslB*₍₁₎ *reoM*^{K23fs} and 10403SΔ*eslB*₍₂₎ *prpC*^{P159L} on BHI plates containing sucrose and penicillin is comparable to the wild-type strain 10403S. The suppressors with mutations in *murZ*, *reoM* and *prpC* also grew like wild-type on BHI plates containing lysozyme as well as on BHI plates that were incubated at 42 °C (Fig. 2A for 10403SΔ*eslB*₍₂₎ *prpC*^{P159L}, data not shown for 10403SΔ*eslB*₍₁₎ *murZ*^{M240fs}, 10403SΔ*eslB*₍₂₎ *murZ*^{Q307fs}, 10403SΔ*eslB*₍₁₎ *reoM*^{K23fs}).

MurZ is a homolog of the UDP-*N*-acetylglucosamine 1-carboxyvinyltransferase MurA, which is required for the first step of peptidoglycan biosynthesis (Fig. 1)(Du et al., 2000; Kock et al., 2004). While MurA is essential for the growth of *L. monocytogenes*, the deletion of *murZ* is possible and results in the stabilization of MurA (Rismondo et al., 2016). MurA is a substrate of the ClpCP protease and a recent study showed that ReoM is required for the ClpCP-dependent proteolytic degradation of



(caption on next page)

Fig. 4. MurA overexpression leads to suppression of *eslB* phenotypes. (A-B) Fosfomycin disk diffusion assay. (A) *L. monocytogenes* strains wt pIMK3, Δ *eslB* pIMK3, wt pIMK3-*murA* and Δ *eslB* pIMK3-*murA* were plated on BHI plates containing 1 mM IPTG. Fosfomycin-soaked disks were placed on the agar surface and the plates incubated for 24 h at 37 °C. Yellow lines indicate the diameter of the zone of inhibition. (B) The inhibition zones for the indicated strains were measured and the average values and standard deviation of three independent experiments were plotted. (C) Drop dilution assay. Dilutions of *L. monocytogenes* strains 10403S pIMK3 (wt pIMK3), Δ *eslB* pIMK3, wt pIMK3-*murA* and Δ *eslB* pIMK3-*murA* were spotted on BHI plates, BHI plates containing 100 μ g/ml lysozyme or containing 0.5 M sucrose and 0.025 μ g/ml penicillin G, which were incubated at 37 °C or on BHI plates, which were incubated at 42 °C. (D) Microscopy images of *L. monocytogenes* strains. Bacterial membranes were stained with Nile red as described in the methods section. Scale bar is 2 μ m. (E) Cell length of *L. monocytogenes* strains shown in panel B. The cell length of 50 cells per strain was determined and the median cell length calculated. The average values and standard deviations of three independent experiments are plotted. For statistical analysis, a one-way ANOVA coupled with Tukey's multiple comparison test was used (** $p \leq 0.01$, *** $p \leq 0.001$, **** $p \leq 0.0001$). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

MurA in *L. monocytogenes* (Rismondo et al., 2016; Wamp et al., 2020). The activity of ReoM is controlled by the serine/threonine kinase PrkA and the cognate phosphatase PrpC. The phosphorylated form of ReoM stimulates peptidoglycan biosynthesis by preventing ClpCP-dependent degradation of MurA, while MurA degradation is enhanced in the presence of non-phosphorylated ReoM (Wamp et al., 2022, 2020). The identified mutations in *murZ* and *reoM* in our suppressor strains lead to frameshifts, and thus to the production of inactive MurZ and ReoM proteins. It has been previously shown that MurA protein levels are increased in *murZ* and *reoM* mutants (Rismondo et al., 2016; Wamp et al., 2020) and we thus assume that this is also the case for the *eslB* suppressor strains 10403S Δ *eslB*₍₁₎ *murZ*^{M240fs}, 10403S Δ *eslB*₍₂₎ *murZ*^{Q307fs} and 10403S Δ *eslB*₍₁₎ *reoM*^{K23fs}. The identified mutation in *prpC* in the suppressor strain 10403S Δ *eslB*₍₂₎ *prpC*^{P159L} leads to the production of a variant of PrpC, in which proline at position 159 is replaced by a leucine, however, it is currently not known whether this amino acid exchange leads to decreased or enhanced activity of PrpC. A decreased activity of PrpC would lead to accumulation of MurA (Wamp et al., 2022), while enhanced activity would result in reduced MurA levels. To assess which affect the P159L mutation in *prpC* has on MurA levels, western blots were performed using a MurAA-specific antibody. Protein samples of *L. monocytogenes* strains EGD-e and EGD-e Δ *clpC* were used as controls. In accordance with previous studies, MurA accumulated in the *clpC* mutant (Rismondo et al., 2016). The production of the mutated PrpC variant, PrpC^{P159L}, also led to a slight accumulation of MurA in the *eslB* mutant background (Fig. 2B). Additionally, no change in MurA levels could be observed for the *eslB* mutant compared to the wildtype strain 10403S (Fig. 2B). These results suggest that while the decrease in peptidoglycan production seen in the *eslB* mutant is not caused by decreased MurA levels, the growth deficit of the *eslB* mutant can be rescued by preventing MurA degradation.

To confirm that the suppression of the *eslB* phenotypes in the strains with mutations in *murZ*, *reoM* or *prpC* is indeed the result of increased MurA protein levels, we integrated a second, IPTG-inducible copy of *murA* into the genome of the *eslB* mutant. First, we determined the resistance towards fosfomycin, which is a known inhibitor of MurA (Fig. 4A-B) (Kahan et al., 1974), for the *L. monocytogenes* wildtype and the *eslB* mutant harboring the empty plasmid pIMK3 or pIMK3-*murA* in the presence of IPTG. Strain 10403S Δ *eslB* pIMK3 is threefold more sensitive to fosfomycin as compared to the cognate wildtype strain. The induction of *murA* expression increases the resistance of strains 10403S pIMK3-*murA* and 10403S Δ *eslB* pIMK3-*murA* (Fig. 4A-B), suggesting that MurA is indeed overproduced in these strains.

Next, we assessed whether the growth phenotypes of the *eslB* mutant can be suppressed by the overexpression of *murA*. In the presence of the inducer IPTG, the growth of strain 10403S Δ *eslB* pIMK3-*murA* was comparable to the corresponding wildtype strain under all conditions tested (Fig. 4C). These results indicate that overproduction of MurA can compensate for the loss of *eslB* and that the suppression of the *eslB* phenotypes in the *murZ*, *reoM* and *prpC* suppressors is likely the result of increased MurA levels.

Interestingly, increased MurA production also leads to the suppression of the cell division defect of the *eslB* mutant. Cells of the *eslB* mutant carrying the empty pIMK3 plasmid have a cell length of $3.19 \pm 0.29 \mu$ m. In contrast, strain 10403S Δ *eslB* pIMK3-*murA* produces cells with a

length of $2.27 \pm 0.03 \mu$ m, a size that is comparable to the length of *L. monocytogenes* wildtype cells (Fig. 4D-E).

Suppression by reduction of the glycosyltransferase activity of PBP A1

Multiple enzymes are involved in the production of lipid II, the peptidoglycan precursor, within the cytoplasm. After its transport across the membrane via MurJ, lipid II is incorporated into the growing glycan strand by glycosyltransferases, which can either be class A penicillin binding proteins (PBPs), monofunctional glycosyltransferases or members of the SEDS (shape, elongation, division, sporulation) family, such as RodA and FtsW (Cho et al., 2016; Emami et al., 2017; Meeske et al., 2016). *L. monocytogenes* encodes two class A PBPs, PBP A1 and PBP A2, in its genome (Korsak et al., 2010; Rismondo et al., 2015). One of the *eslB* suppressor strains, ANG5717, carries a point mutation in *pbpA1* leading to the substitution of glycine at position 125 by aspartate. Interestingly, this glycine residue is part of the catalytic site of the glycosyltransferase domain, suggesting that the glycosyltransferase activity of the PBP A1 variant PBP A1^{G125D} might be reduced. Drop dilution assays and microscopic analysis revealed that the phenotypes associated with deletion of *eslB* can be rescued by *pbpA1*^{G125D} (Fig. 5A-C). The glycosyltransferase activity of class A PBPs can be inhibited by moenomycin (Huber and Neesemann, 1968). We thus tested whether the presence of moenomycin would enable the growth of the *eslB* mutant under heat stress. As shown in Fig. 5D, the *eslB* mutant is unable to grow at 42 °C on BHI plates or BHI plates containing DMSO, which was used to dissolve moenomycin. In contrast, nearly wildtype-like growth of the *eslB* mutant was observed on BHI plates that were supplemented with moenomycin. These results suggest that growth deficits of the *eslB* mutant can be rescued by the reduction of the glycosyltransferase activity of class A PBPs.

Suppression by reducing *cwlo* expression or CwlO activity

In addition to suppressors associated with MurA and PBP A1, we isolated suppressors carrying mutations in genes that either affect the transcription of *cwlo* or the activity of CwlO. CwlO is a Δ -endopeptidase, which opens the existing cell wall to allow for the insertion of new lipid II precursors during cell elongation of *B. subtilis* (Bisicchia et al., 2007; Hashimoto et al., 2012). In *B. subtilis*, transcription of *cwlo* is induced by WalRK in response to low Δ -endopeptidase activity (Bisicchia et al., 2007; Dobihal et al., 2019; Dubrac et al., 2008) and CwlO activity is stimulated by a direct interaction with the ABC transporter FtsEX (Meisner et al., 2013). In our suppressor screen, we isolated eight *eslB* suppressor strains that carried mutations in *walK*, which were either isolated under lysozyme or sucrose penicillin stress, and four *eslB* suppressor strains that carried mutations in *walR* from which the majority was isolated in the presence of lysozyme stress. We selected *eslB* suppressors 10403S Δ *eslB*₍₂₎ *walR*^{S216G} and 10403S Δ *eslB*₍₂₎ *walK*^{H463D}, which were isolated under lysozyme stress, and 10403S Δ *eslB*₍₂₎ *walK*^{I583T}, which was isolated under sucrose penicillin stress, for further analysis. In addition, three suppressors with mutations were isolated in *ftsE*, *ftsX* and *cwlo* under sucrose penicillin pressure (Table 1).

Spot plating assays showed that the *eslB* suppressors with mutations in either *walR* or *walK* could overcome the growth defect of the *eslB*




Fig. 5. Inactivation of the glycosyltransferase of penicillin binding proteins rescues the *eslB* mutant. (A) Drop dilution assay. Dilutions of *L. monocytogenes* strains 10403S (wt), $\Delta eslB_{(3)}$, $\Delta eslB_{(3)}$ compl. and $\Delta eslB_{(3)}$ *pbpA1*^{G125D} were spotted on BHI plates, BHI plates containing 100 μ g/ml lysozyme or containing 0.5 M sucrose and 0.025 μ g/ml penicillin G, which were incubated at 37 °C or on BHI plates, which were incubated at 42 °C. (B) Microscopy images of *L. monocytogenes* strains. Bacterial membranes were stained with Nile red as described in the methods section. Scale bar is 2 μ m. (C) Cell length of *L. monocytogenes* strains shown in panel B. The cell length of 50 cells per strain was determined and the median cell length calculated. The average values and standard deviations of three independent experiments are plotted. (D) Drop dilution assay. Dilutions of *L. monocytogenes* strains 10403S (wt), $\Delta eslB_{(2)}$ and $\Delta eslB_{(2)}$ compl. were spotted on BHI plates, BHI plates containing DMSO or containing 0.025 μ g/ml moenomycin and incubated at 37 °C or 42 °C. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)




Fig. 7. Absence of CwI/O suppresses most of the *eslB* phenotypes. (A) Drop dilution assay. Dilutions of *L. monocytogenes* strains 10403S (wt), $\Delta eslB_{(2)}$, $\Delta cwI/O$ and $\Delta cwI/O \Delta eslB pIMK3-cwI/O$ were spotted on BHI plates, BHI plates containing 100 $\mu\text{g}/\text{ml}$ lysozyme or containing 0.5 M sucrose and 0.025 $\mu\text{g}/\text{ml}$ penicillin G and were incubated at 37 °C or on BHI plates that were incubated at 42 °C. For induction of *cwI/O* expression, the indicated plates were supplemented with 1 mM IPTG. (B) Microscopy images of *L. monocytogenes* strains. Bacterial membranes were stained with Nile red as described in the methods section. Scale bar is 2 μm . (C) Cell length of *L. monocytogenes* strains shown in panel B. The cell length of 50 cells per strain was determined and the median cell length calculated. The average values and standard deviations of three independent experiments are plotted. For statistical analysis, a one-way ANOVA coupled with a Dunnett's multiple comparison test was used (* $p \leq 0.05$, **** $p \leq 0.0001$). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

mutant was constructed, in which the expression of an ectopic copy of *cwI/O* was placed under the control of an IPTG-inducible promoter. As expected, in the absence of the inducer, the *eslB cwI/O* double mutant was able to grow on BHI plates supplemented with sucrose and penicillin. In accordance to the results obtained for the suppressors, the growth of a strain lacking both, EslB and CwI/O, was still impaired in the presence of lysozyme. Furthermore, individual deletion of either *eslB* or *cwI/O* resulted in a severe growth defect at higher temperatures, while the *eslB cwI/O* double mutant was able to grow in the absence of IPTG at 42 °C. Induction of *cwI/O* expression in strain 10403S $\Delta cwI/O \Delta eslB pIMK3-cwI/O$ resulted in a growth defect under sucrose penicillin and under heat stress, which is comparable to that of the *eslB* mutant (Fig. 7A). Next, we studied the cell morphology of strains lacking CwI/O, EslB or both. In accordance with previous studies investigating the function of CwI/O in *B. subtilis* (Domínguez-Cuevas et al., 2013; Meisner et al., 2013), the *L. monocytogenes cwI/O* mutant formed slightly smaller, bent cells (Fig. 7B-C). Cells lacking both, EslB and CwI/O, were also shorter than cells of the *L. monocytogenes* wildtype 10403S, while induction of *cwI/O* expression in strain 10403S $\Delta cwI/O \Delta eslB pIMK3-cwI/O$ resulted in the formation of elongated cells (Fig. 7B-C). Altogether, these findings support our hypothesis that the suppression of the *eslB* phenotypes in the *cwI/O*, *ftsE* and *ftsX* suppressors is the result of an inactivation of the D_L-endopeptidase CwI/O.

Suppression by inhibition of WTA biosynthesis

In *B. subtilis*, WalRK does not only stimulate transcription of *cwI/O*, but also of the *tagAB* and *tagDEFGH* operons, which encode proteins required for WTA biosynthesis and export (Howell et al., 2003). In *L. monocytogenes* 10403S, WTA is composed of a ribitol phosphate backbone, which is attached to a Glc-Glc-glycerol phosphate-GlcNAc-ManNAc linker unit and modified with GlcNAc, rhamnose and D-alanine residues (Brown et al., 2013; Shen et al., 2017). Thus, UDP-GlcNAc is consumed by several enzymes during WTA biosynthesis and modification. As mentioned above, we isolated suppressors containing mutations in *lmo1077*, encoding a TarL homolog, and the promoter region of the *dlt* operon (Table 1). TarL is a teichoic acid ribitol phosphate polymerase required for the polymerization of the ribitol phosphate backbone of WTA (Fig. 1)(Brown et al., 2013). The *dlt* operon codes for proteins that are essential for the D-alanylation of WTA (Neuhaus and Baddiley, 2003; Perego et al., 1995; Rismondo et al., 2021a). Fig. 8A shows that the *eslB* mutant, which harbors a mutation in *tarL*, could grow again under sucrose penicillin and lysozyme stress, likely due to a reduction in WTA biosynthesis and potentially leading to an increase in the cellular UDP-GlcNAc pool, which can then be used by MurA. However, the *tarL* suppressor is unable to grow at 42 °C. A similar phenotype could be observed when the *L. monocytogenes* wildtype strain 10403S is grown at 42 °C on a plate containing high concentrations of tunicamycin, which inhibits TarO, the first enzyme required for WTA biosynthesis (data not shown). This indicates that the mutated TarL variant produced by the *eslB* suppressor strain 10403S $\Delta eslB_{(3)} tarL^{P282L}$ has a reduced activity. To further test if inhibition of WTA biosynthesis is indeed beneficial for the *eslB* mutant, we grew the *eslB* mutant at 42 °C on BHI plates containing different concentrations of tunicamycin. We could see partial suppression of the heat sensitivity at a tunicamycin concentration of 0.05 $\mu\text{g}/\text{ml}$ and the *eslB* mutant grew comparable to the *L. monocytogenes* wildtype strain 10403S and the complementation strain on plates containing 0.5 $\mu\text{g}/\text{ml}$ tunicamycin (Fig. S4). These results demonstrate that reduction of WTA biosynthesis leads to the suppression of the heat phenotype associated of the *eslB* mutant.

Fig. 8A further shows that the *eslB* suppressor strain, which harbors a mutation in the *dlt* promoter region, could grow again under all conditions tested. To assess what consequence the point mutation in the promoter region of the *dlt* operon has on gene expression, we place the promoterless *lacZ* gene under the control of the *dlt* promoter or the mutated *dlt* promoter found in suppressor strain 10403S $\Delta eslB_{(3)} P_{dlt}^*$.




Fig. 8. Suppression of *esIB* phenotypes by alterations in WTA biosynthesis and modification. (A) Drop dilution assay. Dilutions of *L. monocytogenes* strains 10403S (wt), $\Delta esIB_{(3)}$, $\Delta esIB_{(3)}$ compl., $\Delta esIB_{(3)}$ *tarL*^{P282L} and $\Delta esIB_{(3)}$ *P*_{dlt}^{*} were spotted on BHI plates, BHI plates containing 100 μ g/ml lysozyme or containing 0.5 M sucrose and 0.025 μ g/ml penicillin G and were incubated at 37 °C or on BHI plates that were incubated at 42 °C. (B) β -galactosidase assay. The *dlt* promoter of *L. monocytogenes* wildtype 10403S (*P*_{dlt}) and suppressor strain $\Delta esIB_{(3)}$ *P*_{dlt}^{*} (*P*_{dlt}^{*}) were fused with *lacZ* and integrated into the *amyE* locus of *Bacillus subtilis*. The promoter activity was determined in Miller units as described in the methods section and the average and standard deviation of three independent experiments were plotted. An unpaired *t*-test was used for statistical analysis (**** $p \leq 0.0001$). (C) Cytochrome C assay. Cells of *L. monocytogenes* strains 10403S, $\Delta esIB_{(3)}$, $\Delta esIB_{(3)}$ compl. and $\Delta esIB_{(3)}$ *P*_{dlt}^{*} were incubated with cytochrome C as described in the methods section. The percentage of cytochrome C, which is bound by the cell surface, was calculated for three independent experiments and plotted. A strain lacking DltA was used as control. For statistical analysis, a one-way ANOVA coupled with a Dunnett's multiple comparison test was used (** $p \leq 0.01$, **** $p \leq 0.0001$).

The *lacZ* promoter gene fusions were introduced into *B. subtilis* and β -galactosidase activities determined. This analysis showed that the mutation in the *dlt* promoter resulted in increased promoter activity and likely increased D-alanylation of teichoic acids in the suppressor strain (Fig. 8B). The D-alanylation state of teichoic acids is an important factor that impacts the bacterial cell surface charge (Vadyvaloo et al., 2004). As we isolated a suppressor that increased the expression of the *dlt* operon, we wondered, whether the surface charge of *esIB* mutant cells is altered. To test this, we determined the binding capability of positively charged cytochrome C to the cell surface of different *L. monocytogenes* strains, which serves as a readout of the bacterial surface charge (Peschel et al., 1999; Wecke et al., 1997). A strain lacking D-alanine residues on LTA and WTA due to a deletion of *dltA* was used as a control. As expected, the cell surface of the *dltA* mutant had a higher negative charge as compared to the *L. monocytogenes* wildtype strain 10403S. A similar result was observed for the *esIB* mutant. The high negative surface charge of the *esIB* mutant could be partially rescued by the mutation in the *dlt* promoter, which is present in the *esIB* suppressor strain 10403S $\Delta esIB$ *P*_{dlt}^{*} (Fig. 8C). This result suggests that either the D-

alanylation state of WTAs is altered in the absence of EslB or that the surface presentation of WTA is changed due to the production of a thinner peptidoglycan layer.

Discussion

In this study, we aimed to provide further insight into the connection between the predicted ABC transporter EslABC and peptidoglycan biosynthesis. Previous studies have shown that the deletion of *esIB*, coding for one of transmembrane components of the transporter, leads to a growth defect on sucrose containing media, the formation of elongated cells, the production of a thinner peptidoglycan layer, as well as sensitivity towards the natural antibiotic lysozyme and cationic antimicrobial peptides (Burke et al., 2014; Durack et al., 2015; Rismondo et al., 2021b), suggesting its involvement in peptidoglycan biosynthesis and cell division. It was proposed that the addition of Mg²⁺ rescues mutants with a defect in peptidoglycan biosynthesis by reducing the activity of peptidoglycan hydrolases (Tesson et al., 2022). In accordance with this, we observed a suppression of the *esIB* growth deficits under all




Fig. 9. Model of altered WTA presentation on the cell surface of an *eslB* mutant. The Gram-positive cell wall is composed of a thick layer of peptidoglycan (PG) and wall teichoic acids (WTA), which are attached to the MurNAC-moiety of the PG backbone (Brown et al., 2013). WTA of *L. monocytogenes* 10403S are composed of a negatively charged ribitol phosphate backbone (indicated by -), which can be modified with GlcNAc residues (blue hexagons) and positively charged D-alanine residues (indicated by +). The absence of *EslB* seems to affect the production and/or distribution of the PG precursor UDP-GlcNAc between different pathways, which results in the production of a thinner PG layer. WTAs are thought to partially stick out of the PG layer and we propose that due to the thinner PG layer produced by the *eslB* mutant, a larger portion of the WTA backbone, which is negatively charged, could be presented on the bacterial cell surface. This would result in a higher negative cell surface charge of the *eslB* mutant, which would affect the binding capability and/or activity of PG hydrolases, lysozyme and cationic antimicrobial peptides (Low et al., 2011; Ragland and Criss, 2017; Steudle and Pleiss, 2011; Weidenmaier et al., 2003). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

conditions tested when an excess of Mg^{2+} was added. *L. monocytogenes* encodes several peptidoglycan hydrolases, including the DL-endopeptidase CwlO (Spl), the LytM-domain containing protein Lmo2504 and the two cell wall hydrolases NamA and CwhA (p60), which are required for daughter cell separation (Carroll et al., 2003; Pilgrim et al., 2003). We have isolated several *eslB* suppressors, which carry mutations in *cwlO* or mutations in other genes, e.g. *ftsE* or *ftsX*, which affect CwlO activity. After depletion of CwlO, the *eslB* mutant was able to grow in otherwise non-permissive conditions, suggesting that the activity of CwlO might be deregulated in the *eslB* deletion strain or that the peptidoglycan of the *eslB* mutant is more sensitive to hydrolysis by CwlO. CwlO activity is controlled by a direct protein-protein interaction with the ABC transporter FtsEX (Meisner et al., 2013). It is thus tempting to speculate that the ABC transporter *EslABC* might also affect CwlO activity or localization of proteins involved in peptidoglycan biosynthesis and/or degradation. Interestingly, a strain lacking both *EslB* and CwlO is able to grow at elevated temperatures, while both single mutants are not able to grow under this condition.

We could isolate *eslB* suppressor strains with mutations that are associated with stabilization of MurA, the UDP-GlcNAc 1-carboxyvinyltransferase responsible for the first step of peptidoglycan biosynthesis. Elevated levels of MurA, and thus, enhanced peptidoglycan biosynthesis could fully restore the phenotypic defects of the 10403S Δ *eslB* strain. To identify the exact process of peptidoglycan biosynthesis, which is impaired in the *eslB* mutant, we performed a screen with antibiotics targeting different steps of this process. The absence of *eslB* only affected the resistance towards t-Cin and fosfomicin, which reduce the synthesis of UDP-GlcNAc and inhibit MurA, respectively (Marquardt et al., 1994; Pensinger et al., 2021; Sun et al., 2021). Surprisingly, we observed an increased resistance of the *eslB* mutant towards tunicamycin. The primary target of tunicamycin is TarO, the first enzyme of WTA biosynthesis, and, at high concentrations, also *MraY*, which is responsible for the production of lipid I during peptidoglycan biosynthesis (Fig. 1) (Campbell et al., 2011; Hakulinen et al., 2017; Price and Tsvetanova, 2007; Watkinson et al., 1971). During WTA biosynthesis, UDP-GlcNAc is

used for the synthesis of the linker unit and for the modification of the WTA backbone (Eugster et al., 2015; Rismondo et al., 2018; Shen et al., 2017). Thus, reducing the production of WTA could increase the availability of UDP-GlcNAc for peptidoglycan biosynthesis and therefore support the growth of the *eslB* mutant under non-permissive conditions. In accordance with this, we observed a partial suppression of the *eslB* phenotypes by the overproduction of *GlmM* and *GlmR*, two enzymes required for the synthesis of UDP-GlcNAc (Pensinger et al., 2021). These results suggest that either the production or distribution of UDP-GlcNAc as a substrate between different pathways might be disturbed in the *eslB* mutant.

Cell wall stability depends on the balance between peptidoglycan biosynthesis and hydrolysis. An imbalance of one of these processes results in rapid cell lysis (Sassine et al., 2020). Recent studies suggest that new peptidoglycan precursors are inserted into the growing glycan chains by the Rod system, which is composed of several enzymes. In contrast, class A PBPs are thought to fill gaps and/or repair cell wall defects (Cho et al., 2016; Dion et al., 2019; Vigouroux et al., 2020). It was recently shown that enhanced endopeptidase activity leads to the activation of class A PBPs in *E. coli* (Lai et al., 2017). A similar mechanism seems to exist in *B. subtilis*, as either inactivation of PBP1 or inhibition of peptidoglycan hydrolases by the addition of Mg^{2+} suppresses growth and morphological defects of an *mreB* mutant (Tesson et al., 2022). In accordance with this, we also observed suppression of the heat sensitivity of the *eslB* mutant in presence of moenomycin, which specifically inhibits the glycosyltransferase activity of class A PBPs (Ostach and Walker, 2010; Van Heijenoort et al., 1978).

In our suppressor screen, we identified a strain carrying a mutation in the *dlt* promoter region, which leads to an overproduction of the Dlt enzymes. These enzymes are required for the modification of teichoic acids (TAs) with D-alanines (Neuhaus and Baddiley, 2003; Percy and Gründling, 2014; Rismondo et al., 2021a). The modification of TAs with D-alanine residues leads to a reduction in the negative surface charge and affects the activity of peptidoglycan hydrolases (Brown et al., 2013; Tesson et al., 2022; Vadyvaloo et al., 2004). Furthermore, lack of D-

alanine modifications of TAs was shown to increase lysozyme sensitivity in *Staphylococcus aureus* (Herbert et al., 2007). Interestingly, the cell surface of the *eslB* mutant is more negatively charged, similar to that of a strain lacking D-alanine modifications on TAs. Based on our results, we propose the following model: The absence of *EslB* seems to affect the production and/or distribution of UDP-GlcNAc between different pathways, leading to the production of a thinner peptidoglycan layer. The reduced peptidoglycan thickness could subsequently result in the presentation of a larger portion of WTA on the bacterial cell surface, which would explain the higher negative surface charge (Fig. 9). This higher negative surface charge would enhance the binding capability and/or activity of cationic antimicrobial peptides, lysozyme as well as peptidoglycan hydrolases (Low et al., 2011; Neuhaus and Baddiley, 2003; Ragland and Criss, 2017; Steudle and Pleiss, 2011; Weidenmaier et al., 2003) and furthermore explain the sensitivity of the *eslB* mutant towards CwlO activity, lysozyme and cationic antimicrobial peptides (Burke et al., 2014; Rismondo et al., 2021b).

The essential two-component system WalRK stimulates the transcription of several peptidoglycan hydrolases in Gram-positive bacteria (Delaune et al., 2011; Delauné et al., 2012; Dubrac et al., 2008; Dubrac and Msadek, 2004; Howell et al., 2003). In *B. subtilis*, WalRK also regulates the expression of genes involved in WTA biosynthesis and export (Howell et al., 2003). The regulon of the WalRK system has not yet been determined for *L. monocytogenes*, however, it was shown that the system is essential (Fischer et al., 2022). Inactivation of WalRK usually leads to cell death of wildtype cells due to loss of peptidoglycan hydrolase activity, however, cell death could be prevented by the inhibition of peptidoglycan biosynthesis (Salamaga et al., 2021). We have isolated several *eslB* suppressors with mutations in *walR* and *walK*. As it is unlikely that all of these mutations are gain-of-function mutations, we hypothesize that these mutations result in a reduced activity of the WalRK system. This would lead to a reduced peptidoglycan hydrolase activity as well as a reduction in WTA content, and reduction of the latter would at least partially restore the bacterial cell surface charge of the *eslB* mutant.

Taken together, we could show that the lack of *EslB* results in a defect in peptidoglycan biosynthesis, which can be suppressed by modulating the activity of enzymes involved in either peptidoglycan biosynthesis or hydrolysis. Our results suggest that the production or distribution of the peptidoglycan precursor UDP-GlcNAc between different pathways might be disturbed in the *eslB* mutant. Further studies are required to prove this hypothesis and to determine the function of the ABC transporter *EslABC*.

CRedit authorship contribution statement

Lisa Maria Schulz: Conceptualization, Funding acquisition, Investigation, Visualization, Formal analysis, Writing – review & editing. **Patricia Rothe:** Investigation, Formal analysis. **Sven Halbedel:** Supervision, Writing – review & editing. **Angelika Gründling:** Conceptualization, Funding acquisition, Writing – review & editing. **Jeanine Rismondo:** Conceptualization, Funding acquisition, Investigation, Visualization, Formal analysis, Writing – original draft.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgements

We thank Ivan Andrew and Jaspreet Haywood from the CSC Genomics Laboratory, Hammersmith Hospital, for their help with the whole genome sequencing and Annika Gillis for help with genome sequence analysis. We also thank Julia Busse for technical assistance and Tayfun

Acar for the help with some experiments. We are grateful to Prof. Jörg Stülke for providing JR and LMS with laboratory space, equipment and consumables and to the Göttingen Center for Molecular Biosciences (GZMB) for financial support. This work was funded by the Wellcome Trust grant 210671/Z/18/Z and MRC grant MR/P011071/1 to AG, the German research foundation (DFG) grants RI 2920/1-1, RI 2920/2-1 and RI 2920/3-1 to JR, HA 6830/4 to SH. LMS was supported by the Göttingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences (GGNB, DFG grant GSC226/4).

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.tcs.2022.100085>.

References

- Aubry, C., Goulard, C., Nahori, M.-A., Cayet, N., Decalf, J., Sachse, M., Boneca, I.G., Cossart, P., Dussurget, O., 2011. OatA, a peptidoglycan O-acetyltransferase involved in *Listeria monocytogenes* immune escape, is critical for virulence. *J. Infect. Dis.* 204, 731–740. <https://doi.org/10.1093/infdis/jir396>.
- Bisicchia, P., Noone, D., Lioliou, E., Howell, A., Quigley, S., Jensen, T., Jarmer, H., Devine, K.M., 2007. The essential YycFG two-component system controls cell wall metabolism in *Bacillus subtilis*. *Mol. Microbiol.* 65, 180–200. <https://doi.org/10.1111/j.1365-2958.2007.05782.x>.
- Boneca, I.G., Dussurget, O., Cabanes, D., Nahori, M.-A., Sousa, S., Lecuit, M., Psyllinakis, E., Bouriotis, V., Hugot, J.-P., Giovannini, M., Coyle, A., Bertin, J., Namane, A., Rousselle, J.-C., Cayet, N., Prévost, M.-C., Balloy, V., Chignard, M., Philpott, D.J., Cossart, P., Girardin, S.E., 2007. A critical role for peptidoglycan N-deacetylation in *Listeria* evasion from the host innate immune system. *Proc. Natl. Acad. Sci.* 104, 997–1002. <https://doi.org/10.1073/pnas.0609672104>.
- Brown, S., Santa Maria, J.P., Walker, S., 2013. Wall teichoic acids of Gram-positive bacteria. *Annu. Rev. Microbiol.* 67 (1), 313–336.
- Brunet, Y.R., Wang, X., Rudner, D.Z., Kearns, D.B., 2019. SweC and SweD are essential co-factors of the PtsEX-CwlO cell wall hydrolase complex in *Bacillus subtilis*. *PLoS Genet.* 15 (8), e1008296.
- Burke, T.P., Loukitcheva, A., Zemansky, J., Wheeler, R., Boneca, I.G., Portnoy, D.A., 2014. *Listeria monocytogenes* is resistant to lysozyme through the regulation, not the acquisition, of cell wall-modifying enzymes. *J. Bacteriol.* 196, 3756–3767. <https://doi.org/10.1128/JB.02053-14>.
- Camilli, A., Tilney, L.G., Portnoy, D.A., 1993. Dual roles of *plcA* in *Listeria monocytogenes* pathogenesis. *Mol. Microbiol.* 8, 143–157. <https://doi.org/10.1111/j.1365-2958.1993.tb01211.x>.
- Campbell, J., Singh, A.K., Santa Maria, J.P., Kim, Y., Brown, S., Swoboda, J.G., Mylonakis, E., Wilkinson, B.J., Walker, S., 2011. Synthetic lethal compound combinations reveal a fundamental connection between wall teichoic acid and peptidoglycan biosyntheses in *Staphylococcus aureus*. *ACS Chem. Biol.* 6 (1), 106–116.
- Carballido-López, R., Formstone, A., Li, Y., Ehrlich, S.D., Noirot, P., Errington, J., 2006. Actin homolog MreBH governs cell morphogenesis by localization of the cell wall hydrolase LytE. *Dev. Cell* 11, 399–409. <https://doi.org/10.1016/j.devcel.2006.07.017>.
- Carroll, S.A., Hain, T., Technow, U., Darji, A., Pashalidis, P., Joseph, S.W., Chakraborty, T., 2003. Identification and characterization of a peptidoglycan hydrolase, MurA, of *Listeria monocytogenes*, a muramidase needed for cell separation. *J. Bacteriol.* 185, 6801–6808. <https://doi.org/10.1128/JB.185.23.6801-6808.2003>.
- Cho, H., Wivagg, C.N., Kapoor, M., Barry, Z., Rohs, P.D.A., Suh, H., Marto, J.A., Garner, E.C., Bernhardt, T.G., 2016. Bacterial cell wall biogenesis is mediated by SEDS and PBP polymerase families functioning semi-autonomously. *Nat. Microbiol.* 1, 16172. <https://doi.org/10.1038/nmicrobiol.2016.172>.
- Delauné, A., Dubrac, S., Blanchet, C., Poupel, O., Mäder, U., Hiron, A., Leduc, A., Fitting, C., Nicolas, P., Cavaillon, J.-M., Adib-Conquy, M., Msadek, T., Camilli, A., 2012. The WalkR system controls major staphylococcal virulence genes and is involved in triggering the host inflammatory response. *Infect. Immun.* 80 (10), 3438–3453.
- Delaune, A., Poupel, O., Mallet, A., Coic, Y.-M., Msadek, T., Dubrac, S., Horschburgh, M., 2011. Peptidoglycan crosslinking relaxation plays an important role in *Staphylococcus aureus* WalkR-dependent cell viability. *PLoS One* 6 (2), e17054.
- Dion, M.F., Kapoor, M., Sun, Y., Wilson, S., Ryan, J., Vigouroux, A., van Teeffelen, S., Oldenbourg, R., Garner, E.C., 2019. *Bacillus subtilis* cell diameter is determined by the opposing actions of two distinct cell wall synthetic systems. *Nat. Microbiol.* 4, 1294–1305. <https://doi.org/10.1038/s41564-019-0439-0>.
- Dobihal, G.S., Brunet, Y.R., Flores-Kim, J., Rudner, D.Z., 2019. Homeostatic control of cell wall hydrolysis by the WalRK two-component signaling pathway in *Bacillus subtilis*. *Elife* 8, e52088.
- Domínguez-Cuevas, P., Porcelli, I., Daniel, R.A., Errington, J., 2013. Differentiated roles for MreB-actin isologues and autolytic enzymes in *Bacillus subtilis* morphogenesis. *Mol. Microbiol.* 89, 1084–1098. <https://doi.org/10.1111/mmi.12335>.
- Du, W., Brown, J.R., Sylvester, D.R., Huang, J., Chalker, A.F., So, C.Y., Holmes, D.J., Payne, D.J., Wallis, N.G., 2000. Two active forms of UDP-N-acetylglucosamine

- enolpyruvyl transferase in gram-positive bacteria. *J. Bacteriol.* 182, 4146–4152. <https://doi.org/10.1128/JB.182.15.4146-4152.2000>.
- Dubrac, S., Bisicchia, P., Devine, K.M., Msadek, T., 2008. A matter of life and death: cell wall homeostasis and the WalKR (YycGF) essential signal transduction pathway. *Mol. Microbiol.* 70, 1307–1322. <https://doi.org/10.1111/j.1365-2958.2008.06483.x>.
- Dubrac, S., Msadek, T., 2004. Identification of genes controlled by the essential YycG/YycF two-component system of *Staphylococcus aureus*. *J. Bacteriol.* 186, 1175–1181. <https://doi.org/10.1128/JB.186.4.1175-1181.2004>.
- Durack, J., Burke, T.P., Portnoy, D.A., Schneewind, O., 2015. A *prl* mutation in SecY suppresses secretion and virulence defects of *Listeria monocytogenes secA2* mutants. *J. Bacteriol.* 197 (5), 932–942.
- Emami, K., Guyet, A., Kawai, Y., Devi, J., Wu, L.J., Allenby, N., Daniel, R.A., Errington, J., 2017. RodA as the missing glycosyltransferase in *Bacillus subtilis* and antibiotic discovery for the peptidoglycan polymerase pathway. *Nat. Microbiol.* 2, 16253. <https://doi.org/10.1038/nmicrobiol.2016.253>.
- Eugster, M.R., Morax, L.S., Hüls, V.J., Huwiler, S.G., Leclercq, A., Lecuit, M., Loessner, M. J., 2015. Bacteriophage predation promotes serovar diversification in *Listeria monocytogenes*. *Mol. Microbiol.* 97, 33–46. <https://doi.org/10.1111/mmi.13009>.
- Fischer, M.A., Engelgeh, T., Rothe, P., Fuchs, S., Thürmer, A., Halbedel, S., 2022. *Listeria monocytogenes* genes supporting growth under standard laboratory cultivation conditions and during macrophage infection. *Genome Res.* 32, 1711–1726. <https://doi.org/10.1101/gr.276747.122>.
- Hakulinen, J.K., Hering, J., Brändén, G., Chen, H., Snijder, A., Ek, M., Johansson, P., 2017. MraY-antibiotic complex reveals details of tunicamycin mode of action. *Nat. Chem. Biol.* 13, 265–267. <https://doi.org/10.1038/nchembio.2270>.
- Hashimoto, M., Ooiwa, S., Sekiguchi, J., 2012. Synthetic lethality of the *lytE cwI*O genotype in *Bacillus subtilis* is caused by lack of D, L-endopeptidase activity at the lateral cell wall. *J. Bacteriol.* 194, 796–803. <https://doi.org/10.1128/JB.05569-11>.
- Herbert, S., Bera, A., Nerz, C., Kraus, D., Peschel, A., Goerke, C., Meehl, M., Cheung, A., Götz, F., Weiser, J.N., 2007. Molecular basis of resistance to muramidase and cationic antimicrobial peptide activity of lysozyme in staphylococci. *PLoS Pathog.* 3 (7), e102.
- Howell, A., Dubrac, S., Andersen, K.K., Noone, D., Fert, J., Msadek, T., Devine, K., 2003. Genes controlled by the essential YycG/YycF two-component system of *Bacillus subtilis* revealed through a novel hybrid regulator approach. *Mol. Microbiol.* 49, 1639–1655. <https://doi.org/10.1046/j.1365-2958.2003.03661.x>.
- Huber, G., Nesemann, G., 1968. Moenomycin, an inhibitor of cell wall synthesis. *Biochem. Biophys. Res. Commun.* 30, 7–13. [https://doi.org/10.1016/0006-291x\(68\)90704-3](https://doi.org/10.1016/0006-291x(68)90704-3).
- Kahan, F.M., Kahan, J.S., Cassidy, P.J., Kropp, H., 1974. The mechanism of action of fosfomycin (phosphonomycin). *Ann. N.Y. Acad. Sci.* 235, 364–386. <https://doi.org/10.1111/j.1749-6632.1974.tb43277.x>.
- Kang, J., Wiedmann, M., Boor, K.J., Bergholz, T.M., Griffiths, M.W., 2015. VirR-Mediated resistance of *Listeria monocytogenes* against food antimicrobials and cross-protection induced by exposure to organic acid salts. *Appl. Environ. Microbiol.* 81 (13), 4553–4562.
- Kock, H., Gerth, U., Hecker, M., 2004. MurAA, catalysing the first committed step in peptidoglycan biosynthesis, is a target of Clp-dependent proteolysis in *Bacillus subtilis*. *Mol. Microbiol.* 51, 1087–1102. <https://doi.org/10.1046/j.1365-2958.2003.03875.x>.
- Korsak, D., Markiewicz, Z., Gutkind, G.O., Ayala, J.A., 2010. Identification of the full set of *Listeria monocytogenes* penicillin-binding proteins and characterization of PBPD2 (Lmo2812). *BMC Microbiol.* 10, 239. <https://doi.org/10.1186/1471-2180-10-239>.
- Lai, G.C., Cho, H., Bernhardt, T.G., Hughes, D., 2017. The mecillinam resistome reveals a role for peptidoglycan endopeptidases in stimulating cell wall synthesis in *Escherichia coli*. *PLoS Genet.* 13 (7), e1006934.
- Lauer, P., Chow, M.Y.N., Loessner, M.J., Portnoy, D.A., Calendar, R., 2002. Construction, characterization, and use of two *Listeria monocytogenes* site-specific phage integration vectors. *J. Bacteriol.* 184, 4177–4186. <https://doi.org/10.1128/JB.184.15.4177-4186.2002>.
- Leclercq, S., Derouaux, A., Olatunji, S., Fraipont, C., Egan, A.J.F., Vollmer, W., Breukink, E., Terrak, M., 2017. Interplay between penicillin-binding proteins and SEDS proteins promotes bacterial cell wall synthesis. *Sci. Rep.* 7, 43306. <https://doi.org/10.1038/srep43306>.
- Low, L.Y., Yang, C., Perego, M., Osterman, A., Liddington, R., 2011. Role of net charge on catalytic domain and influence of cell wall binding domain on bactericidal activity, specificity, and host range of phage lysins. *J. Biol. Chem.* 286, 34391–34403. <https://doi.org/10.1074/jbc.M111.244160>.
- Marquardt, J.L., Brown, E.D., Lane, W.S., Haley, T.M., Ichikawa, Y., Wong, C.H., Walsh, C.T., 1994. Kinetics, stoichiometry, and identification of the reactive thiolate in the inactivation of UDP-GlcNAc enolpyruvyl transferase by the antibiotic fosfomycin. *Biochemistry* 33, 10646–10651. <https://doi.org/10.1021/bi00201a011>.
- Marston, A.L., Thomaidis, H.B., Edwards, D.H., Sharpe, M.E., Errington, J., 1998. Polar localization of the MinD protein of *Bacillus subtilis* and its role in selection of the mid-cell division site. *Genes Dev.* 12, 3419–3430. <https://doi.org/10.1101/gad.12.21.3419>.
- Meeske, A.J., Sham, L.-T., Kimsey, H., Koo, B.-M., Gross, C.A., Bernhardt, T.G., Rudner, D.Z., 2015. MurJ and a novel lipid II flippase are required for cell wall biogenesis in *Bacillus subtilis*. *Proc. Natl. Acad. Sci.* 112, 6437–6442. <https://doi.org/10.1073/pnas.1504967112>.
- Meeske, A.J., Riley, E.P., Robins, W.P., Uehara, T., Mekalanos, J.J., Kahne, D., Walker, S., Kruse, A.C., Bernhardt, T.G., Rudner, D.Z., 2016. SEDS proteins are a widespread family of bacterial cell wall polymerases. *Nature* 537, 634–638. <https://doi.org/10.1038/nature19331>.
- Meisner, J., Montero Llopis, P., Sham, L.-T., Garner, E., Bernhardt, T.G., Rudner, D.Z., 2013. FtsEX is required for CwlO peptidoglycan hydrolase activity during cell wall elongation in *Bacillus subtilis*. *Mol. Microbiol.* 89, 1069–1083. <https://doi.org/10.1111/mmi.12330>.
- Miller, J.H., 1972. *Experiments in Molecular Genetics*. Cold Spring Harbor Laboratory, NY.
- Neuhaus, F.C., Baddiley, J., 2003. A continuum of anionic charge: structures and functions of D-alanyl-teichoic acids in Gram-positive bacteria. *Microbiol. Mol. Biol. Rev.* 67, 686–723. <https://doi.org/10.1128/MMBR.67.4.686-723.2003>.
- Ohnishi, R., Ishikawa, S., Sekiguchi, J.P., 1999. Peptidoglycan hydrolase LytF plays a role in cell separation with CwlF during vegetative growth of *Bacillus subtilis*. *J. Bacteriol.* 181, 3178–3184. <https://doi.org/10.1128/JB.181.10.3178-3184.1999>.
- Ostash, B., Walker, S., 2010. Moenomycin family antibiotics: chemical synthesis, biosynthesis, and biological activity. *Nat. Prod. Rep.* 27, 1594–1617. <https://doi.org/10.1039/c001461n>.
- Pazos, M., Peters, K., 2019. Peptidoglycan. *Subcell. Biochem.* 92, 127–168. https://doi.org/10.1007/978-3-030-18768-2_5.
- Pensinger, D.A., Gutierrez, K. V., Smith, H.B., Vincent, W.J.B., Stevenson, D.S., Black, K. A., Perez-Medina, K.M., Dillard, J.P., Rhee, K.Y., Amador-Noguez, D., Huynh, T.N., Sauer, J.-D., 2021. *Listeria monocytogenes* GlnR is an accessory uridylyltransferase essential for cytosolic survival and virulence. *bioRxiv* 2021.10.27.466214. <https://doi.org/10.1101/2021.10.27.466214>.
- Percy, M.G., Gründling, A., 2014. Lipoteichoic acid synthesis and function in Gram-positive bacteria. *Annu. Rev. Microbiol.* 68, 81–100. <https://doi.org/10.1146/annurev-micro-091213-112949>.
- Perego, M., Glaser, P., Minutello, A., Strauch, M.A., Leopold, K., Fischer, W., 1995. Incorporation of D-alanine into lipoteichoic acid and wall teichoic acid in *Bacillus subtilis*. Identification of genes and regulation. *J. Biol. Chem.* 270, 15598–15606. <https://doi.org/10.1074/jbc.270.26.15598>.
- Peschel, A., Otto, M., Jack, R.W., Kalbacher, H., Jung, G., Götz, F., 1999. Inactivation of the *dlt* operon in *Staphylococcus aureus* confers sensitivity to defensins, protegrins, and other antimicrobial peptides. *J. Biol. Chem.* 274, 8405–8410. <https://doi.org/10.1074/jbc.274.13.8405>.
- Pilgrim, S., Kolb-Mäurer, A., Gentschev, I., Goebel, W., Kuhn, M., 2003. Deletion of the gene encoding *p60* in *Listeria monocytogenes* leads to abnormal cell division and loss of actin-based motility. *Infect. Immun.* 71, 3473–3484. <https://doi.org/10.1128/IAI.71.6.3473-3484.2003>.
- Price, N.P.J., Tsvetanova, B., 2007. Biosynthesis of the tunicamycins: a review. *J. Antibiot. (Tokyo)* 60, 485–491. <https://doi.org/10.1038/ja.2007.62>.
- Ragland, S.A., Criss, A.K., Bliska, J.B., 2017. From bacterial killing to immune modulation: Recent insights into the functions of lysozyme. *PLoS Pathog.* 13 (9), e1006512.
- Rismondo, J., Möller, L., Aldridge, C., Gray, J., Vollmer, W., Halbedel, S., 2015. Discrete and overlapping functions of peptidoglycan synthases in growth, cell division and virulence of *Listeria monocytogenes*. *Mol. Microbiol.* 95, 332–351. <https://doi.org/10.1111/mmi.12873>.
- Rismondo, J., Bender, J.K., Halbedel, S., 2016. Suppressor mutations linking *gpsB* with the first committed step of peptidoglycan biosynthesis in *Listeria monocytogenes*. *J. Bacteriol.* 199, e00393–e00416. <https://doi.org/10.1128/JB.00393-16>.
- Rismondo, J., Percy, M.G., Gründling, A., 2018. Discovery of genes required for lipoteichoic acid glycosylation predicts two distinct mechanisms for wall teichoic acid glycosylation. *J. Biol. Chem.* 293, 3293–3306. <https://doi.org/10.1074/jbc.RA117.001614>.
- Rismondo, J., Gillis, A., Gründling, A., 2021a. Modifications of cell wall polymers in Gram-positive bacteria by multi-component transmembrane glycosylation systems. *Curr. Opin. Microbiol.* 60, 24–33. <https://doi.org/10.1016/j.mib.2021.01.007>.
- Rismondo, J., Schulz, L.M., 2021. Not just transporters: Alternative functions of ABC transporters in *Bacillus subtilis* and *Listeria monocytogenes*. *Microorganisms* 9, 163. <https://doi.org/10.3390/microorganisms9010163>.
- Rismondo, J., Schulz, L.M., Yacoub, M., Wadhawan, A., Hoppert, M., Dionne, M.S., Gründling, A., 2021b. EsIB is required for cell wall biosynthesis and modification in *Listeria monocytogenes*. *J. Bacteriol.* 203, e00553–e00620. <https://doi.org/10.1128/JB.00553-20>.
- Ruiz, N., 2008. Bioinformatics identification of MurJ (MviN) as the peptidoglycan lipid II flippase in *Escherichia coli*. *Proc. Natl. Acad. Sci. U. S. A.* 105, 15553–15557. <https://doi.org/10.1073/pnas.0808352105>.
- Salamaga, B., Kong, L., Pasquina-Lemonche, L., Lafage, L., von und zur Muhlen, M., Gibson, J.F., Grybchuk, D., Tooke, A.K., Panchal, V., Culp, E.J., Tatham, E., O’Kane, M.E., Catley, T.E., Renshaw, S.A., Wright, G.D., Plevka, P., Bullough, P.A., Han, A., Hobbs, J.K., Foster, S.J., 2021. Demonstration of the role of cell wall homeostasis in *Staphylococcus aureus* growth and the action of bactericidal antibiotics. *e2106022118 Proc. Natl. Acad. Sci.* 118 (44). <https://doi.org/10.1073/pnas.2106022118>.
- Sarkar, P., Yarlagadda, V., Ghosh, C., Haldar, J., 2017. A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics. *Medchemcomm* 8, 516–533. <https://doi.org/10.1039/c6md00585c>.
- Sassine, J., Sousa, J., Lalk, M., Daniel, R.A., Vollmer, W., 2020. Cell morphology maintenance in *Bacillus subtilis* through balanced peptidoglycan synthesis and hydrolysis. *Sci. Rep.* 10, 17910. <https://doi.org/10.1038/s41598-020-74609-5>.
- Sham, L.-T., Butler, E.K., Lebar, M.D., Kahne, D., Bernhardt, T.G., Ruiz, N., 2014. Bacterial cell wall. MurJ is the flippase of lipid-linked precursors for peptidoglycan biogenesis. *Science* 345, 220–222. <https://doi.org/10.1126/science.1254522>.
- Shen, Y., Boulos, S., Sumrall, E., Gerber, B., Julian-Rodero, A., Eugster, M.R., Fieseler, L., Nyström, L., Ebert, M.-O., Loessner, M.J., 2017. Structural and functional diversity in *Listeria* cell wall teichoic acids. *J. Biol. Chem.* 292, 17832–17844. <https://doi.org/10.1074/jbc.M117.813964>.

- Soldo, B., Lazarevic, V., Karamata, D., 2002. *tagO* is involved in the synthesis of all anionic cell-wall polymers in *Bacillus subtilis* 168. *Microbiology* 148, 2079–2087. <https://doi.org/10.1099/00221287-148-7-2079>.
- Steudle, A., Pleiss, J., 2011. Modelling of lysozyme binding to a cation exchange surface at atomic detail: the role of flexibility. *Biophys. J.* 100, 3016–3024. <https://doi.org/10.1016/j.bpj.2011.05.024>.
- Sun, L., Rogiers, G., Michiels, C.W., 2021. The natural antimicrobial *trans*-Cinnamaldehyde interferes with UDP-N-acetylglucosamine biosynthesis and cell wall homeostasis in *Listeria monocytogenes*. *Foods* 10, 1666. <https://doi.org/10.3390/foods10071666>.
- Taguchi, A., Welsh, M.A., Marmont, L.S., Lee, W., Sjodt, M., Kruse, A.C., Kahne, D., Bernhardt, T.G., Walker, S., 2019. FtsW is a peptidoglycan polymerase that is functional only in complex with its cognate penicillin-binding protein. *Nat. Microbiol.* 4, 587–594. <https://doi.org/10.1038/s41564-018-0345-x>.
- Takada, H., Shiwa, Y., Takino, Y., Osaka, N., Ueda, S., Watanabe, S., Chibazakura, T., Su'etsugu, M., Utsumi, R., Yoshikawa, H., 2018. Essentiality of WalRK for growth in *Bacillus subtilis* and its role during heat stress. *Microbiology* 164 (4), 670–684.
- Tesson, B., Dajkovic, A., Keary, R., Marlière, C., Dupont-Gillain, C.C., Carballido-López, R., 2022. Magnesium rescues the morphology of *Bacillus subtilis mreB* mutants through its inhibitory effect on peptidoglycan hydrolases. *Sci. Rep.* 12, 1137. <https://doi.org/10.1038/s41598-021-04294-5>.
- Vadyvaloo, V., Arous, S., Gravesen, A., Héchar, Y., Chauhan-Haubrock, R., Hastings, J. W., Rautenbach, M., 2004. Cell-surface alterations in class IIa bacteriocin-resistant *Listeria monocytogenes* strains. *Microbiology* 150, 3025–3033. <https://doi.org/10.1099/mic.0.27059-0>.
- Van Heijenoort, Y., Derrien, M., Van Heijenoort, J., 1978. Polymerization by transglycosylation in the biosynthesis of the peptidoglycan of *Escherichia coli* K 12 and its inhibition by antibiotics. *FEBS Lett.* 89, 141–144. [https://doi.org/10.1016/0014-5793\(78\)80540-7](https://doi.org/10.1016/0014-5793(78)80540-7).
- Vigouroux, A., Cordier, B., Aristov, A., Alvarez, L., Özbaykal, G., Chaze, T., Oldewurtel, E.R., Matondo, M., Cava, F., Bikard, D., van Teeffelen, S., 2020. Class-A penicillin binding proteins do not contribute to cell shape but repair cell-wall defects. *Elife* 9, e51998.
- Vollmer, W., Joris, B., Charlier, P., Foster, S., 2008. Bacterial peptidoglycan (murein) hydrolases. *FEMS Microbiol. Rev.* 32, 259–286. <https://doi.org/10.1111/j.1574-6976.2007.00099.x>.
- Wamp, S., Rutter, Z.J., Rismondo, J., Jennings, C.E., Möller, L., Lewis, R.J., Halbedel, S., 2020. PrkA controls peptidoglycan biosynthesis through the essential phosphorylation of ReoM. *Elife* 9, e56048.
- Wamp, S., Rothe, P., Stern, D., Holland, G., Döhling, J., Halbedel, S., Sassetti, C.M., 2022. MurA escape mutations uncouple peptidoglycan biosynthesis from PrkA signaling. *PLoS Pathog.* 18 (3), e1010406.
- Watkinson, R.J., Hussey, H., Baddiley, J., 1971. Shared lipid phosphate carrier in the biosynthesis of teichoic acid and peptidoglycan. *Nat. New Biol.* 229, 57–59. <https://doi.org/10.1038/newbio229057a0>.
- Wecke, J., Madela, K., Fischer, W., 1997. The absence of D-alanine from lipoteichoic acid and wall teichoic acid alters surface charge, enhances autolysis and increases susceptibility to methicillin in *Bacillus subtilis*. *Microbiology* 143, 2953–2960. <https://doi.org/10.1099/00221287-143-9-2953>.
- Weidenmaier, C., Kristian, S.A., Peschel, A., 2003. Bacterial resistance to antimicrobial host defenses—an emerging target for novel anti-infective strategies? *Curr. Drug Targets* 4, 643–649. <https://doi.org/10.2174/1389450033490731>.
- Yamaguchi, H., Furuhashi, K., Fukushima, T., Yamamoto, H., Sekiguchi, J., 2004. Characterization of a new *Bacillus subtilis* peptidoglycan hydrolase Gene, *yvcE* (named *cwlO*), and the enzymatic properties of its encoded protein. *J. Biosci. Bioeng.* 98, 174–181. <https://doi.org/10.1263/jbb.98.174>.